JavaScript 似乎在您的浏览器中被禁用。 为了您在我们网站能获得最好的体验，建议在浏览器中打开Javascript。

若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系。

跳转到图像库的开头

EasySep™小鼠TIL（CD45）正选试剂盒

小鼠CD45+ TIL免疫磁珠正选

只有 %1 左

率先评论此产品

¥5,916.00

产品号 #（选择产品）

产品号 #100-0350_C

小鼠CD45+ TIL免疫磁珠正选

产品优势

操作简单、快捷，且无需分离柱
针对肿瘤和CD45起始占比低的组织样本进行优化
实验方法可灵活调整以实现更高的纯度或回收率

产品组分包括

EasySep™小鼠TIL （CD45）正选抗体混合物组分A， 0.25 mL
EasySep™小鼠TIL （CD45）正选抗体混合物组分B， 0.25 mL
EasySep™小鼠TIL （CD45）正选抗体混合物组分C， 1.5 mL
EasySep™ Dextran RapidSpheres™ 50100 磁珠，2 x 1 mL

立即询价

要查看实验方案所需的所有配套产品，请参阅《实验方案与技术文档》。

EasyEights™ EasySep™磁极
EasySep™缓冲液

总览

实验数据

产品说明书及文档

应用领域

总览

使用EasySep™小鼠TIL（CD45）正选试剂盒，通过免疫磁珠正选轻松分离高纯度的小鼠CD45+肿瘤浸润白细胞（TIL）。该试剂盒已针对小鼠实体瘤的单细胞悬液进行了优化，包括将4T1、B16-F10和CT26.WT细胞系植入同品系小鼠来诱导的肿瘤。由于不同小鼠肿瘤的异质性，该试剂盒可能需要优化。EasySep™技术结合单克隆抗体的特异性和无柱磁分选系统的简便性，已在发表的研究中广泛应用超过20年。

在该EasySep™正选流程中，目标细胞通过识别CD45的抗体复合物和磁珠进行标记，并通过EasySep™磁极分选。只需简单倾倒或吸取以弃去非目的细胞，而目的细胞则保留在试管中。磁珠分选后，目的CD45+ TIL可立即用于流式细胞术、培养和基于细胞的实验等下游应用。

了解更多关于EasySep™免疫磁珠分选技术的工作原理。探索更多为您实验流程优化的其它产品，包括培养基、补充剂、抗体等。

磁极兼容性
• EasySep™磁极（产品号 #18000）
• “The Big Easy” EasySep™磁极（产品号 #18001）
• EasyEights™ EasySep™磁极（产品号 #18103）

分类
细胞分选试剂盒

细胞类型
白细胞

种属
小鼠

样本来源
其他组织，肿瘤

分选方法
正选

应用
细胞分选

品牌
EasySep

研究领域
癌症，免疫

查看更多显示更少

实验数据

$Using the EasySep™ Mouse TIL (CD45) Positive Selection Kit, the CD45+ TIL purities of the start and final isolated fractions are 14.8% and 95.2%, respectively for B16-F10 tumor single-cell suspension, 37.6% and 93.0%, respectively for 4T1 tumor single-cell suspension, and 32.3% and 84.6%, respectively for CT26.WT tumor single-cell suspension.$ $Using the EasySep™ Mouse TIL (CD45) Positive Selection Kit, the CD45+ TIL purities of the start and final isolated fractions are 14.8% and 95.2%, respectively for B16-F10 tumor single-cell suspension, 37.6% and 93.0%, respectively for 4T1 tumor single-cell suspension, and 32.3% and 84.6%, respectively for CT26.WT tumor single-cell suspension.$ $Using the EasySep™ Mouse TIL (CD45) Positive Selection Kit, the CD45+ TIL purities of the start and final isolated fractions are 14.8% and 95.2%, respectively for B16-F10 tumor single-cell suspension, 37.6% and 93.0%, respectively for 4T1 tumor single-cell suspension, and 32.3% and 84.6%, respectively for CT26.WT tumor single-cell suspension.$

Figure 1. Typical EasySep™ Mouse TIL (CD45) Cell Isolation Profile

Tumors were induced by B16-F10, 4T1, or CT26.WT cell lines and dissociated into single-cell suspensions. CD45+ TILs were isolated from single-cell suspensions at various start concentrations using the purple EasySep™ Magnet.

(A) Starting with a B16-F10 tumor single-cell suspension at 1 x 10⁸ cells/mL, the purities of the start and final isolated fractions are 14.8% and 95.2%, respectively.

(B) Starting with a 4T1 tumor single-cell suspension at 4 x 10⁷ cells/mL, the purities of the start and final isolated fractions are 37.6% and 93.0%, respectively.

(C) Starting with a CT26.WT tumor single-cell suspension at 2.5 x 10⁷ cells/mL, the purities of the start and final isolated fractions are 32.3% and 84.6%, respectively.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type

Product Name

Catalog #

Lot #

Language

Document Type

产品说明书

Product Name

EasySep™小鼠TIL（CD45）正选试剂盒

Catalog #

100-0350

Lot #

All

Language

中文

Document Type

Product Information Sheet

Product Name

EasySep™ Mouse TIL (CD45) Positive Selection Kit

Catalog #

100-0350

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

EasySep™ Mouse TIL (CD45) Positive Selection Kit

Catalog #

100-0350

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

EasySep™ Mouse TIL (CD45) Positive Selection Kit

Catalog #

100-0350

Lot #

All

Language

English

Document Type

Safety Data Sheet 3

Product Name

EasySep™ Mouse TIL (CD45) Positive Selection Kit

Catalog #

100-0350

Lot #

All

Language

English

Document Type

Safety Data Sheet 4

Product Name

EasySep™ Mouse TIL (CD45) Positive Selection Kit

Catalog #

100-0350

Lot #

All

Language

English

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

Research Area

Workflow Stages

Workflow Stages for B Cell Research

Cell Sourcing

Cell Isolation

Cell Expansion

Cell Characterization

Workflow Stages for Dendritic Cell Research

Cell Sourcing

Cell Isolation

Cell Differentiation and Maturation

Cell Characterization

Workflow Stages for Granulocyte Research

Cell Sourcing

Cell Isolation

Cell Characterization

Workflow Stages for Total Lymphocyte Research

Cell Sourcing

Cell Isolation

Cell Characterization

Workflow Stages for Monocyte Research

Cell Sourcing

Cell Isolation

Cell Differentiation and Maturation

Cell Characterization

Workflow Stages for Myeloid Cell Research

Cell Sourcing

Cell Isolation

Cell Differentiation & Maturation

Cell Characterization

Workflow Stages for Natural Killer Cell Research

Cell Sourcing

Cell Isolation

Cell Expansion and Differentiation

Cell Characterization

Workflow Stages for T Cell Research

Cell Sourcing

Cell Isolation

Cell Activation, Expansion, and Differentiation

Cell Characterization

Workflow Stages for T Cell Engineering

Cell Isolation

Cell Activation, Expansion, and Differentiation

Cell Characterization

Cell Cryopreservation

Workflow Stages for Innate Lymphoid Cell Research

Cell Sourcing

Cell Isolation

Cell Culture and Characterization

相关材料与文献

Network-based screening identifies sitagliptin as an antitumor drug targeting dendritic cells Journal for Immunotherapy of Cancer 2024 Mar

Abstract

BackgroundDendritic cell (DC)-mediated antigen presentation is essential for the priming and activation of tumor-specific T cells. However,few drugs that specifically manipulate DC functions are available. The identification of drugs targeting DC holds great promise for cancer immunotherapy.MethodsWe observed that type 1 conventional DCs (cDC1s) initiated a distinct transcriptional program during antigen presentation. We used a network-based approach to screen for cDC1-targeting therapeutics. The antitumor potency and underlying mechanisms of the candidate drug were investigated in vitro and in vivo.ResultsSitagliptin,an oral gliptin widely used for type 2 diabetes,was identified as a drug that targets DCs. In mouse models,sitagliptin inhibited tumor growth by enhancing cDC1-mediated antigen presentation,leading to better T-cell activation. Mechanistically,inhibition of dipeptidyl peptidase 4 (DPP4) by sitagliptin prevented the truncation and degradation of chemokines/cytokines that are important for DC activation. Sitagliptin enhanced cancer immunotherapy by facilitating the priming of antigen-specific T cells by DCs. In humans,the use of sitagliptin correlated with a lower risk of tumor recurrence in patients with colorectal cancer undergoing curative surgery.ConclusionsOur findings indicate that sitagliptin-mediated DPP4 inhibition promotes antitumor immune response by augmenting cDC1 functions. These data suggest that sitagliptin can be repurposed as an antitumor drug targeting DC,which provides a potential strategy for cancer immunotherapy.

View publication

S-adenosylmethionine metabolism shapes CD8+ T cell functions in colorectal cancer Cancer & Metabolism 2025 May

Abstract

Metabolite nutrients within the tumor microenvironment shape both tumor progression and immune cell functionality. It remains elusive how the metabolic interaction between T cells and tumor cells results in different anti-cancer immunotherapeutic responses. Here,we use untargeted metabolomics to investigate the metabolic heterogeneity in patients with colorectal cancer (CRC). Our analysis reveals enhanced S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) metabolism in microsatellite stable (MSS) CRC,a subtype known for its resistance to immunotherapy. Functional studies reveal that SAM and SAH enhance the initial activation and effector functions of CD8+ T cells. Instead,cancer cells outcompete CD8+ T cells for SAM and SAH availability to impair T cell survival. In vivo,SAM supplementation promotes T cell proliferation and reduces exhaustion of the tumor-infiltrating CD8+ T cells,thus suppressing tumor growth in tumor-bearing mice. This study uncovers the metabolic crosstalk between T cells and tumor cells,which drives the development of tumors resistant to immunotherapy.Supplementary InformationThe online version contains supplementary material available at 10.1186/s40170-025-00394-2.

View publication

View All Publications

物种	小鼠
Magnet Compatibility	• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103)
样本来源	其它细胞系, 肿瘤
Selection Method	Positive

EasySep™小鼠TIL（CD45）正选试剂盒

产品号 #100-0350

产品号 #（选择产品）

产品号 #100-0350_C

产品优势

产品组分包括

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

Request Pricing

更多信息

Scientists Helping Scientists™

EasySep™小鼠TIL（CD45）正选试剂盒

产品号 #100-0350

产品号 #（选择产品）

产品号 #100-0350_C

产品优势

产品组分包括

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

技术资料 (13)

文献 (2)

Abstract

Abstract

Request Pricing

更多信息

欢迎您关注STEMCELL Technologies的微信公众平台